277 related articles for article (PubMed ID: 2680140)
21. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis.
Katoch K; Singh P; Adhikari T; Benara SK; Singh HB; Chauhan DS; Sharma VD; Lavania M; Sachan AS; Katoch VM
Vaccine; 2008 Feb; 26(9):1228-34. PubMed ID: 18243430
[TBL] [Abstract][Full Text] [Related]
22. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years.
Sharma P; Mukherjee R; Talwar GP; Sarathchandra KG; Walia R; Parida SK; Pandey RM; Rani R; Kar H; Mukherjee A; Katoch K; Benara SK; Singh T; Singh P
Lepr Rev; 2005 Jun; 76(2):127-43. PubMed ID: 16038246
[TBL] [Abstract][Full Text] [Related]
23. [The protective efficacy of BCG against leprosy in São Paulo, Brazil].
Lombardi C; Pedrazzani ES; Pedrazzani JC; Ferreira Filho P; Zicker F
Bol Oficina Sanit Panam; 1995 Nov; 119(5):415-21. PubMed ID: 8540997
[TBL] [Abstract][Full Text] [Related]
24. The Karimui trial of BCG. 2. Tuberculin reactions in a leprosy-endemic but tuberculosis-free population.
Scott GC; Wigley SG; Russell DA
Int J Lepr Other Mycobact Dis; 1966; 34(2):139-46. PubMed ID: 5330190
[No Abstract] [Full Text] [Related]
25. Protective efficacy of BCG against leprosy in São Paulo.
Lombardi C; Pedrazzani ES; Pedrazzani JC; Filho PF; Zicker F
Bull Pan Am Health Organ; 1996 Mar; 30(1):24-30. PubMed ID: 8919722
[TBL] [Abstract][Full Text] [Related]
26. Protective effect of BCG against leprosy and its subtypes: a case-control study in southern Vietnam.
Thuc NV; Abel L; Lap VD; Oberti J; Lagrange PH
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):532-8. PubMed ID: 7868950
[TBL] [Abstract][Full Text] [Related]
27. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity.
Fine PE; Sterne JA; Pönnighaus JM; Rees RJ
Lancet; 1994 Nov; 344(8932):1245-9. PubMed ID: 7967984
[TBL] [Abstract][Full Text] [Related]
28. Effect of BCG on the risk of leprosy in an endemic area: a case control study.
Muliyil J; Nelson KE; Diamond EL
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):229-36. PubMed ID: 2071979
[TBL] [Abstract][Full Text] [Related]
29. Tuberculosis prevention: where do we go from here?
Warndorff DK
Afr Health; 1996 Nov; 19(1):21-2. PubMed ID: 12291917
[TBL] [Abstract][Full Text] [Related]
30. The effect of Bacille Calmette-Guérin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis.
Araujo Z; de Waard JH; de Larrea CF; Borges R; Convit J
Vaccine; 2008 Oct; 26(44):5575-81. PubMed ID: 18723065
[TBL] [Abstract][Full Text] [Related]
31. Anti-leprosy protective vaccination of rhesus monkeys with BCG or BCG plus heat-killed Mycobacterium leprae: lepromin skin test results.
Gormus BJ; Baskin GB; Xu K; Ratterree MS; Mack PA; Bohm RP; Meyers WM; Walsh GP
Lepr Rev; 2002 Sep; 73(3):254-61. PubMed ID: 12449891
[TBL] [Abstract][Full Text] [Related]
32. Borderline tuberculoid leprosy following BCG vaccination. A case report.
Stoner GL; Belehu A; Nsibambi J; Warndorff J
Int J Lepr Other Mycobact Dis; 1981 Mar; 49(1):16-20. PubMed ID: 7195879
[TBL] [Abstract][Full Text] [Related]
33. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine.
Comstock GW
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S250-3. PubMed ID: 10875793
[TBL] [Abstract][Full Text] [Related]
34. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?
Menzies D
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S71-4. PubMed ID: 11010826
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.
Leung CC; Tam CM; Chan SL; Chan-Yeung M; Chan CK; Chang KC
Int J Tuberc Lung Dis; 2001 Aug; 5(8):717-23. PubMed ID: 11495262
[TBL] [Abstract][Full Text] [Related]
36. [Problems in designing a protocol for a leprosy vaccine trial. (author's transl)].
Sansarricq H
Rev Epidemiol Sante Publique; 1981; 29(3):305-14. PubMed ID: 7029677
[TBL] [Abstract][Full Text] [Related]
37. [A retrospective study on tuberculin in children under 19].
Herranz Alvarez M; Vázquez Gallardo R; Minguella García I; Chouciño Garrido N; Otero Baamonde MI; Quiles Sotillo P
An Esp Pediatr; 1996 Mar; 44(3):234-8. PubMed ID: 8830597
[TBL] [Abstract][Full Text] [Related]
38. The distribution and implications of BCG scars in northern Malawi.
Fine PE; Ponnighaus JM; Maine N
Bull World Health Organ; 1989; 67(1):35-42. PubMed ID: 2706726
[TBL] [Abstract][Full Text] [Related]
39. [Tuberculosis infection prevalence in children younger than 7 years of age in Cantabria. What is the recommended periodicity for the tuberculin tes?].
Rollán Rollán A; Bonilla Miera C; González de Aledo Linos A; Diego Santamaría MC; Obeso García M; Montes Conde A
An Esp Pediatr; 1997 Mar; 46(3):241-4. PubMed ID: 9173842
[TBL] [Abstract][Full Text] [Related]
40. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size.
Floyd S; Ponnighaus JM; Bliss L; Warndorff DK; Kasunga A; Mogha P; Fine PE
Int J Tuberc Lung Dis; 2000 Dec; 4(12):1133-42. PubMed ID: 11144455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
